Loading...
Real-world use of PCSK9 inhibitors: A single-center experience
OBJECTIVE: Hyperlipidemia is an important risk factor for atherosclerotic cardiovascular disease. Many patients are intolerant to or have limited benefit from statins. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been approved for treating hyperlipidemia in these patients. W...
Na minha lista:
| Udgivet i: | J Int Med Res |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
SAGE Publications
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6384467/ https://ncbi.nlm.nih.gov/pubmed/30280628 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0300060518800595 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|